How much profit has MDxHealth made this year?
MDxHealth has made -141.4 M USD this year.
MDxHealth Net Income 2024
MDxHealth Net Income
-141.4 M USD
Ticker
MDXH.BR
ISIN
BE0003844611
WKN
A0J3N3
In 2024, MDxHealth's profit amounted to -141.4 M USD, a -21.73% increase from the -180.64 M USD profit recorded in the previous year.
The MDxHealth Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2027e | 16.62 |
| 2026e | 2.67 |
| 2025e | -9.19 |
| 2024e | -141.4 |
| 2023e | -180.64 |
| 2022 | -44.04 |
| 2021 | -29 |
| 2020 | -28.66 |
| 2019 | -43.1 |
| 2018 | -32.45 |
| 2017 | -12.29 |
| 2016 | -13.17 |
| 2015 | -14.47 |
| 2014 | -15.26 |
| 2013 | -16.18 |
| 2012 | -11.53 |
| 2011 | -9.67 |
| 2010 | -10.93 |
| 2009 | -19.89 |
| 2008 | -14.91 |
| 2007 | -13.66 |
| 2006 | -9.25 |
| 2005 | -5.32 |
| 2004 | -6.45 |
| 2003 | -4.58 |
MDxHealth Revenue, EBIT, Net Income BE0003844611 · A0J3N3
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into MDxHealth, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MDxHealth from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MDxHealth’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of MDxHealth. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into MDxHealth’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing MDxHealth’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MDxHealth’s growth potential.
MDxHealth Revenue, EBIT and net profit per share
| Date | MDxHealth Revenue | MDxHealth EBIT | MDxHealth Net Income |
|---|---|---|---|
| 2027e | 129.96 M undefined | 18.07 M undefined | 16.62 M undefined |
| 2026e | 113.21 M undefined | 3.96 M undefined | 2.67 M undefined |
| 2025e | 112.2 M undefined | -10.78 M undefined | -9.19 M undefined |
| 2024e | 83.28 M undefined | -20.91 M undefined | -141.4 M undefined |
| 2023e | 70.75 M undefined | -27.38 M undefined | -180.64 M undefined |
| 2022 | 37.05 M undefined | -37.86 M undefined | -44.04 M undefined |
| 2021 | 22.24 M undefined | -26.84 M undefined | -29 M undefined |
| 2020 | 18.46 M undefined | -26.85 M undefined | -28.66 M undefined |
| 2019 | 11.79 M undefined | -36.88 M undefined | -43.1 M undefined |
| 2018 | 28.4 M undefined | -32.1 M undefined | -32.45 M undefined |
| 2017 | 40.51 M undefined | -12.27 M undefined | -12.29 M undefined |
| 2016 | 29.97 M undefined | -12.85 M undefined | -13.17 M undefined |
| 2015 | 17.64 M undefined | -14.38 M undefined | -14.47 M undefined |
| 2014 | 11.67 M undefined | -15.34 M undefined | -15.26 M undefined |
| 2013 | 7.55 M undefined | -16.07 M undefined | -16.18 M undefined |
| 2012 | 5.91 M undefined | -11.44 M undefined | -11.53 M undefined |
| 2011 | 3.74 M undefined | -9.88 M undefined | -9.67 M undefined |
| 2010 | 3.36 M undefined | -11.08 M undefined | -10.93 M undefined |
| 2009 | 3.54 M undefined | -20.49 M undefined | -19.89 M undefined |
| 2008 | 4.42 M undefined | -16.57 M undefined | -14.91 M undefined |
| 2007 | 3.62 M undefined | -15.02 M undefined | -13.66 M undefined |
| 2006 | 3.48 M undefined | -9.84 M undefined | -9.25 M undefined |
| 2005 | 3.83 M undefined | -5.39 M undefined | -5.32 M undefined |
| 2004 | 480,000 undefined | -6.52 M undefined | -6.45 M undefined |
| 2003 | 0 undefined | -4.52 M undefined | -4.58 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2003 | 0 USD | -4.52 M USD | -4.58 M USD |
| 2004 | 480,000 USD | -6.52 M USD | -6.45 M USD |
| 2005 | 3.83 M USD | -5.39 M USD | -5.32 M USD |
| 2006 | 3.48 M USD | -9.84 M USD | -9.25 M USD |
| 2007 | 3.62 M USD | -15.02 M USD | -13.66 M USD |
| 2008 | 4.42 M USD | -16.57 M USD | -14.91 M USD |
| 2009 | 3.54 M USD | -20.49 M USD | -19.89 M USD |
| 2010 | 3.36 M USD | -11.08 M USD | -10.93 M USD |
| 2011 | 3.74 M USD | -9.88 M USD | -9.67 M USD |
| 2012 | 5.91 M USD | -11.44 M USD | -11.53 M USD |
| 2013 | 7.55 M USD | -16.07 M USD | -16.18 M USD |
| 2014 | 11.67 M USD | -15.34 M USD | -15.26 M USD |
| 2015 | 17.64 M USD | -14.38 M USD | -14.47 M USD |
| 2016 | 29.97 M USD | -12.85 M USD | -13.17 M USD |
| 2017 | 40.51 M USD | -12.27 M USD | -12.29 M USD |
| 2018 | 28.4 M USD | -32.1 M USD | -32.45 M USD |
| 2019 | 11.79 M USD | -36.88 M USD | -43.1 M USD |
| 2020 | 18.46 M USD | -26.85 M USD | -28.66 M USD |
| 2021 | 22.24 M USD | -26.84 M USD | -29 M USD |
| 2022 | 37.05 M USD | -37.86 M USD | -44.04 M USD |
| 2023e | 70.75 M USD | -27.38 M USD | -180.64 M USD |
| 2024e | 83.28 M USD | -20.91 M USD | -141.4 M USD |
| 2025e | 112.2 M USD | -10.78 M USD | -9.19 M USD |
| 2026e | 113.21 M USD | 3.96 M USD | 2.67 M USD |
| 2027e | 129.96 M USD | 18.07 M USD | 16.62 M USD |
MDxHealth stock margins BE0003844611 · A0J3N3
The MDxHealth margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MDxHealth. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MDxHealth.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the MDxHealth's sales revenue. A higher gross margin percentage indicates that the MDxHealth retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the MDxHealth's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the MDxHealth's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MDxHealth's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MDxHealth. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MDxHealth's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
MDxHealth Margin History
| MDxHealth Gross margin | MDxHealth Profit margin | MDxHealth EBIT margin | MDxHealth Profit margin |
|---|---|---|---|
| 2027e | 51.74 % | 13.91 % | 12.79 % |
| 2026e | 51.74 % | 3.5 % | 2.36 % |
| 2025e | 51.74 % | -9.61 % | -8.19 % |
| 2024e | 51.74 % | -25.11 % | -169.78 % |
| 2023e | 51.74 % | -38.71 % | -255.34 % |
| 2022 | 51.74 % | -102.19 % | -118.87 % |
| 2021 | 46.81 % | -120.68 % | -130.4 % |
| 2020 | 43.01 % | -145.45 % | -155.25 % |
| 2019 | -1.19 % | -312.81 % | -365.56 % |
| 2018 | 57.89 % | -113.03 % | -114.26 % |
| 2017 | 73.54 % | -30.29 % | -30.34 % |
| 2016 | 61.13 % | -42.88 % | -43.94 % |
| 2015 | 53.06 % | -81.52 % | -82.03 % |
| 2014 | 44.73 % | -131.45 % | -130.76 % |
| 2013 | 23.31 % | -212.85 % | -214.3 % |
| 2012 | 80.37 % | -193.57 % | -195.09 % |
| 2011 | 90.11 % | -264.17 % | -258.56 % |
| 2010 | 85.42 % | -329.76 % | -325.3 % |
| 2009 | 92.94 % | -578.81 % | -561.86 % |
| 2008 | 92.08 % | -374.89 % | -337.33 % |
| 2007 | 82.87 % | -414.92 % | -377.35 % |
| 2006 | 97.99 % | -282.76 % | -265.8 % |
| 2005 | 96.34 % | -140.73 % | -138.9 % |
| 2004 | 97.92 % | -1,358.33 % | -1,343.75 % |
| 2003 | 51.74 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2003 | 51.74 % | 0 % | 0 % |
| 2004 | 97.92 % | -1,358.33 % | -1,343.75 % |
| 2005 | 96.34 % | -140.73 % | -138.9 % |
| 2006 | 97.99 % | -282.76 % | -265.8 % |
| 2007 | 82.87 % | -414.92 % | -377.35 % |
| 2008 | 92.08 % | -374.89 % | -337.33 % |
| 2009 | 92.94 % | -578.81 % | -561.86 % |
| 2010 | 85.42 % | -329.76 % | -325.3 % |
| 2011 | 90.11 % | -264.17 % | -258.56 % |
| 2012 | 80.37 % | -193.57 % | -195.09 % |
| 2013 | 23.31 % | -212.85 % | -214.3 % |
| 2014 | 44.73 % | -131.45 % | -130.76 % |
| 2015 | 53.06 % | -81.52 % | -82.03 % |
| 2016 | 61.13 % | -42.88 % | -43.94 % |
| 2017 | 73.54 % | -30.29 % | -30.34 % |
| 2018 | 57.89 % | -113.03 % | -114.26 % |
| 2019 | -1.19 % | -312.81 % | -365.56 % |
| 2020 | 43.01 % | -145.45 % | -155.25 % |
| 2021 | 46.81 % | -120.68 % | -130.4 % |
| 2022 | 51.74 % | -102.19 % | -118.87 % |
| 2023e | 51.74 % | -38.71 % | -255.34 % |
| 2024e | 51.74 % | -25.11 % | -169.78 % |
| 2025e | 51.74 % | -9.61 % | -8.19 % |
| 2026e | 51.74 % | 3.5 % | 2.36 % |
| 2027e | 51.74 % | 13.91 % | 12.79 % |
MDxHealth Aktienanalyse
What does MDxHealth do?
MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding MDxHealth's Profit Margins
The profit margins of MDxHealth represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of MDxHealth's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating MDxHealth's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
MDxHealth's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When MDxHealth’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about MDxHealth stock
How has the profit developed compared to last year?
The profit has increased by -21.73% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does MDxHealth publish its earnings?
MDxHealth publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of MDxHealth?
The profits of MDxHealth are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of MDxHealth?
You can learn more about the earnings of MDxHealth by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does MDxHealth pay?
Over the past 12 months, MDxHealth paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MDxHealth is expected to pay a dividend of 0 USD.
What is the dividend yield of MDxHealth?
The current dividend yield of MDxHealth is .
When does MDxHealth pay dividends?
MDxHealth pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MDxHealth?
MDxHealth paid dividends every year for the past 0 years.
What is the dividend of MDxHealth?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MDxHealth located?
MDxHealth is assigned to the 'Health' sector.
Wann musste ich die Aktien von MDxHealth kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MDxHealth from 10/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/19/2024.
When did MDxHealth pay the last dividend?
The last dividend was paid out on 10/19/2024.
What was the dividend of MDxHealth in the year 2023?
In the year 2023, MDxHealth distributed 0 USD as dividends.
In which currency does MDxHealth pay out the dividend?
The dividends of MDxHealth are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von MDxHealth
Our stock analysis for MDxHealth Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MDxHealth Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
